Sernova Biotherapeutics Inc
SEOVF
$0.12
$0.001.52%
OTC PK
| 10/31/2025 | 07/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -10.63% | -7.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -32.21% | -16.32% | |||
| Operating Income | 32.21% | 16.32% | |||
| Income Before Tax | 44.98% | -12.09% | |||
| Income Tax Expenses | -357.14% | -40.54% | |||
| Earnings from Continuing Operations | 46.60% | -11.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 46.60% | -11.57% | |||
| EBIT | 32.21% | 16.32% | |||
| EBITDA | 31.78% | 17.91% | |||
| EPS Basic | 46.67% | -11.11% | |||
| Normalized Basic EPS | 45.61% | -14.00% | |||
| EPS Diluted | 46.67% | -11.11% | |||
| Normalized Diluted EPS | 45.61% | -14.00% | |||
| Average Basic Shares Outstanding | 0.07% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.07% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||